JP2022545802A - 有機化合物 - Google Patents

有機化合物 Download PDF

Info

Publication number
JP2022545802A
JP2022545802A JP2022511279A JP2022511279A JP2022545802A JP 2022545802 A JP2022545802 A JP 2022545802A JP 2022511279 A JP2022511279 A JP 2022511279A JP 2022511279 A JP2022511279 A JP 2022511279A JP 2022545802 A JP2022545802 A JP 2022545802A
Authority
JP
Japan
Prior art keywords
alkyl
hypertension
substituted
independently
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022511279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545802A5 (https=
Inventor
イー デイビス，ロバート
リ，ポン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2022545802A publication Critical patent/JP2022545802A/ja
Publication of JP2022545802A5 publication Critical patent/JP2022545802A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022511279A 2019-08-22 2020-08-21 有機化合物 Pending JP2022545802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962890162P 2019-08-22 2019-08-22
US62/890,162 2019-08-22
PCT/US2020/047451 WO2021035157A1 (en) 2019-08-22 2020-08-21 Organic compounds

Publications (2)

Publication Number Publication Date
JP2022545802A true JP2022545802A (ja) 2022-10-31
JP2022545802A5 JP2022545802A5 (https=) 2023-08-10

Family

ID=74659635

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511279A Pending JP2022545802A (ja) 2019-08-22 2020-08-21 有機化合物

Country Status (4)

Country Link
US (1) US20220280517A1 (https=)
EP (1) EP4017858A4 (https=)
JP (1) JP2022545802A (https=)
WO (1) WO2021035157A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526395A (ja) * 2012-06-18 2015-09-10 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物
US20160038494A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Novel combination
JP2017523219A (ja) * 2014-08-07 2017-08-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US20180057494A1 (en) * 2016-08-25 2018-03-01 Eli Lilly And Company Triazolopyrazinone derivative useful as a human pde1 inhibitor
JP2019503389A (ja) * 2016-02-12 2019-02-07 イーライ リリー アンド カンパニー Ｐｄｅ１阻害剤
WO2019152697A1 (en) * 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses
WO2019156861A1 (en) * 2018-02-06 2019-08-15 Eli Lilly And Company [1,2,4]triazolo[4,3-a]pyrazin-8-one derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2012070040A1 (en) * 2010-11-26 2012-05-31 Technion Research And Development Foundation Ltd Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
WO2022026417A1 (en) * 2020-07-26 2022-02-03 Intra-Cellular Therapies, Inc. Novel uses
MX2023008755A (es) * 2021-01-27 2023-08-02 Intra Cellular Therapies Inc Cristales de sal.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526395A (ja) * 2012-06-18 2015-09-10 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物
US20160038494A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Novel combination
JP2017523219A (ja) * 2014-08-07 2017-08-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP2019503389A (ja) * 2016-02-12 2019-02-07 イーライ リリー アンド カンパニー Ｐｄｅ１阻害剤
US20180057494A1 (en) * 2016-08-25 2018-03-01 Eli Lilly And Company Triazolopyrazinone derivative useful as a human pde1 inhibitor
WO2019152697A1 (en) * 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses
WO2019156861A1 (en) * 2018-02-06 2019-08-15 Eli Lilly And Company [1,2,4]triazolo[4,3-a]pyrazin-8-one derivatives

Also Published As

Publication number Publication date
US20220280517A1 (en) 2022-09-08
EP4017858A4 (en) 2023-09-27
WO2021035157A1 (en) 2021-02-25
EP4017858A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
JP6638036B2 (ja) 有機化合物
US9624230B2 (en) Organic compounds
JP5911854B2 (ja) 有機化合物
KR101918909B1 (ko) ６­사이클로알킬­１，５­디하이드로­피라졸로［３，４­ｄ］피리미딘­４­온 유도체 및 이의 ｐｄｅ９ａ 억제제로서의 용도
US10398698B2 (en) Uses
KR20110095881A (ko) 유기 화합물
KR20110103949A (ko) 유기 화합물
KR20190058678A (ko) c-MET 억제제로서의 피리돈계　화합물
KR20110096032A (ko) 유기 화합물
EP2755976B1 (en) 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US9931319B2 (en) Carboxamide derivatives
US20250214989A1 (en) Naphthyridinone derivatives for the treatment of a disease or disorder
JP2022545802A (ja) 有機化合物
JP2023535224A (ja) 新規使用
HK40130208A (en) Naphthyridinone derivatives for the treatment of a disease or disorder
HK40109683A (en) Naphthyridinone derivatives for the treatment of a disease or disorder
HK40109683B (en) Naphthyridinone derivatives for the treatment of a disease or disorder
BR112015023592B1 (pt) Compostos orgânicos inibidores de pde1, composição farmacêutica que compreende os mesmos e uso terapêutico dos ditos compostos e da dita composição

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241126